Antiprotozoal Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antiprotozoal Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
- by Diseases
- Amoebic Dysentery
- Antimalarial Drug
- Leishmaniasis & Chagas Disease
- by Drugs
- Metronidazole
- Atovaquone
- Benznidazole
- Dehydroemetine
- Eflornithine
- Emetine
- Fenbendazole
- Iodoquinol
- Melarsoprol
- Others (like Meglumine antimonite, Nifurtimox, Pentamidine, etc.)
Segment by Application
By Company
- Sanofi
- Akthelia Pharmaceuticals Ltd
- GlaxoSmithKline Plc
- Immuron Ltd
- Microbiotix Inc
- Protein Potential LLC
- Dr. Reddy?s Laboratories
- Mission Pharmacal
- Aceto Corp.
- Mylan Pharmaceuticals
- Impax Laboratories
- Pfizer
- Lupin Pharmaceuticals
- Glenmark Pharmaceuticals
- Sun Pharmaceutical
- Heritage Pharmaceuticals
- Gilead Sciences
- Johnson & Johnson
- Bristol-Myers Squibb
- Profounda
- Knight Therapeutics
- Albert David
- Wanlong
- Fangsheng
- KPC Pharmaceuticals
- Guilin Pharmaceuticals
- Pude Pharmaceutica
By Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
